The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).
 
Mary E.R. O'Brien
Employment - Takeda (I)
Honoraria - Boehringer Ingelheim; MSD; Pfizer; Pierre Fabre
Consulting or Advisory Role - Boehringer Ingelheim; MSD; Pfizer; Pierre Fabre
 
Baktiar Hasan
No Relationships to Disclose
 
Urania Dafni
Honoraria - Amgen
 
Jessica Menis
No Relationships to Disclose
 
Solange Peters
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche/Genentech
 
Michele De Waele
No Relationships to Disclose
 
Rolf A. Stahel
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Speakers' Bureau - Astellas Pharma; Boehringer Ingelheim; Merck Sharp & Dohme
 
Paul Van Schil
No Relationships to Disclose
 
George Coukos
No Relationships to Disclose
 
Sylvie Lantuejoul
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche
Research Funding - Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Keith M. Kerr
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; pfizer; Roche/Genentech
 
Ignacio Melero
No Relationships to Disclose
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Luis G. Paz-Ares
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Pfizer; Roche/Genentech